Skip to content

Effects of Esketamine Combined with Midazolam Analgesic Sedation on Respiratory Mechanics in Patients with Mechanical Ventilation--Randomized controlled study

Effects of Esketamine Combined with Midazolam Analgesic Sedation on Respiratory Mechanics in Patients with Mechanical Ventilation

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070733
Enrollment
Unknown
Registered
2023-04-21
Start date
2023-04-25
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome

Interventions

Test group:Analgesic protocol using Esketamine
control group:Analgesia protocol using Remifentanil

Sponsors

Tangdu Hospital of the Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age>18 2) Patients diagnosed with ARDS 3) Mechanical ventilation is required (according to the Clinical Application Guide of Mechanical Ventilation) and the expected ventilation time is>72h 4) Analgesic and sedative treatment is required 5) The client of the patient voluntarily signs the informed consent form

Exclusion criteria

Exclusion criteria: 1) Maternity 2) Known allergy to Esketamine 3) Patients with a history of dementia or mental illness or taking antipsychotic or antidepressant drugs at home 4) Respiratory diseases, such as lobectomy, rib fracture compression fixation 5) Take antihypertensive drugs irregularly, have poor blood pressure control (hypertension grade 2), have a history of tachycardia (heart rate>120 times/min), and risk of brain injury and intracranial hypertension 6) Take M receptor blockers and M receptor stimulants in the last three days; ß 2 receptor blocker 7) Treatment with neuromuscular junction blockers (NMBDs) 8) Extracorporeal membrane oxygenation (ECMO) support therapy 9) The patient gives up resuscitation or is expected to die within 24 hours 10)He has participated in other clinical trials within three months.

Design outcomes

Primary

MeasureTime frame
airway resistance;Static lung compliance;peak airway pressure;plateau pressure;

Secondary

MeasureTime frame
Oxygenation index;PaO2;PaCO2;SpO2;mean arterial pressure;PCT;IL-6;white blood cell count;Percentage of neutrophils;

Countries

China

Contacts

Public ContactYao Linong

Tangdu Hospital of the Fourth Military Medical University

yaoln@fmmu.edu.cn+86 13571837529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026